Plain-English translation of NCT05603884 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a treatment approach using Venetoclax combined with two other medications (Chidamide and Azacitidine) followed by a second medication combination for older adults with a newly diagnosed blood cancer called acute myeloid leukemia. The goal is to see if adding Chidamide to this treatment can help the medication work better and keep the cancer from coming back longer than current treatments do.
Older adults with this type of blood cancer often cannot tolerate the standard, intensive chemotherapy treatments that younger patients receive. While the medication combination Venetoclax and Azacitidine has shown promise in these patients, the cancer typically returns within about a year, so researchers are testing whether adding another drug can improve these results.
You likely qualify if…
You likely don't qualify if…
You would receive two cycles of the first medication combination (given over several weeks), followed by two cycles of a second medication combination, and then this four-cycle course would repeat once more. You would need to attend clinic visits regularly for blood tests, physical exams, and to receive your medications. The entire treatment course would last several months, and you would be monitored closely throughout to track how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China